Trifluridine-Tipiracil with and without Bevacizumab in Colorectal Cancer.

Maliha Nusrat¹, Ruizhi Zhao², Nadeem Khan², Yuexi Wang³, Kathryn L Penney³, Christopher G Cann⁴, Tehseen Salimi²

¹Memorial Sloan Kettering Cancer Center, New York, NY, USA.

²Taiho Oncology, Inc., Princeton, NJ, USA.

³ConcertAI, LLC, Cambridge, MA, USA.

⁴Fox Chase Cancer Center, Philadelphia, PA, USA.

PubMed DOI

Abstract

BACKGROUND: In the phase 3 SUNLIGHT trial (Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients), trifluridine-tipiracil+bevacizumab (FTD-TPI+bev) improved the overall survival of patients with metastatic colorectal cancer (mCRC) compared with trifluridine-tipiracil (FTD-TPI) monotherapy. We investigated the real-world outcomes of FTD-TPI…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.